Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Andre

Showing results (301-310 of 330) with videos related to

Pageof 33
Sort By:
British Journal of Haematology|October 10, 2025
Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignanciesAbi Vijenthira, Sita Bhella, Katrina Hueniken, et al.
NEJM Evidence|June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's LymphomaAngie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Communications Biology|July 30, 2021
Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of actionRachel L Palte, Veronica Juan, Yacob Gomez-Llorente, et al.
Communications Biology|November 16, 2021
Author Correction: Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of actionRachel L Palte, Veronica Juan, Yacob Gomez-Llorente, et al.
Leukemia|October 7, 2018
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA studyRoch Houot, Guillaume Cartron, Fontanet Bijou, et al.
Frontiers in Immunology|February 5, 2025
Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infectionsDana Unninayar, Emilia L Falcone, Hugo Chapdelaine, et al.
Transplantation and Cellular Therapy|November 10, 2025
Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular TherapyC Arianne Buchan, Gerard Agbayani, Katrina Hueniken, et al.
American Journal of Ophthalmology|May 22, 2017
ReplyAudrey de Parisot, Yvan Jamilloux, Laurent Kodjikian, et al.
American Journal of Ophthalmology|April 4, 2017
Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE)Audrey de Parisot, Laurent Kodjikian, Marie-Hélène Errera, et al.
Hemasphere|January 14, 2022
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell LymphomaRoch Houot, Viola Poeschel, Bettina Altmann, et al.
Pageof 33

Showing results (301-310 of 330) with videos related to

Sort By:
Pageof 33
British Journal of Haematology|October 10, 2025
Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignanciesAbi Vijenthira, Sita Bhella, Katrina Hueniken, et al.
NEJM Evidence|June 19, 2025
An Individualized Prediction Model for Early-Stage Classic Hodgkin's LymphomaAngie Mae Rodday, Andrew M Evens, Matthew J Maurer, et al.
Communications Biology|July 30, 2021
Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of actionRachel L Palte, Veronica Juan, Yacob Gomez-Llorente, et al.
Communications Biology|November 16, 2021
Author Correction: Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of actionRachel L Palte, Veronica Juan, Yacob Gomez-Llorente, et al.
Leukemia|October 7, 2018
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA studyRoch Houot, Guillaume Cartron, Fontanet Bijou, et al.
Frontiers in Immunology|February 5, 2025
Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infectionsDana Unninayar, Emilia L Falcone, Hugo Chapdelaine, et al.
Transplantation and Cellular Therapy|November 10, 2025
Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular TherapyC Arianne Buchan, Gerard Agbayani, Katrina Hueniken, et al.
American Journal of Ophthalmology|May 22, 2017
ReplyAudrey de Parisot, Yvan Jamilloux, Laurent Kodjikian, et al.
American Journal of Ophthalmology|April 4, 2017
Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE)Audrey de Parisot, Laurent Kodjikian, Marie-Hélène Errera, et al.
Hemasphere|January 14, 2022
Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell LymphomaRoch Houot, Viola Poeschel, Bettina Altmann, et al.
Pageof 33